COPD: bronchial and systemic inflammation;EPOC: inflamación bronquial y sistémica

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL. 4, 2010, Pages 9-15

  Macario, Ciro Casanova ^a   Torres Tajes, Juan Pablo de ^b   Lanus, Elizabeth Córdoba ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Genetics; Immunity; Inflammation

Indexed keywords

ALPHA 1 ANTITRYPSIN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; CYTOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANEMIA; ARTICLE; BRONCHITIS; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CYTOKINE PRODUCTION; DIABETES MELLITUS; FORCED EXPIRATORY VOLUME; HEREDITY; HUMAN; INNATE IMMUNITY; LUNG CANCER; OSTEOPOROSIS; PHENOTYPE; RESPIRATORY TRACT INFLAMMATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL;

BRONCHITIS; HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77956997711     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70027-2     Document Type: Article

References (77)

1. Peces-Barba G., Barberá J.A., Agusti A., Casanova C., Casas A., Izquierdo J.L., et al. Guía de práctica clínica de diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. Normativa SEPAR-ALAT. Arch Bronconeumol 2008, 44:271-281.
2. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist A.S., Calverley P., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for chronic obstructive pulmonary disease (GOLD). Workshop summary. Am J Respir Crit Care Med 2007, 176:532-555. Update 2009.
3. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364:709-721.
4. Hogg J.C., Chu F., Utokaparch B., Woods R., Elliot W.M., Buzatu L., et al. The natures of small-airway obstruction in chronic obstructive pulmonary disease. New Engl J Med 2004, 350:2645-2653.
5. Barnes P.J., Chowdhury B., Kharitonov S.A., Magnussen H., Page C.P., Postma D., Saetta M. Pulmonary biomarkers in COPD. Am J Respir Crit Care Med 2006, 174:6-14.
6. O'Shaughnessy T.C., Ansari T.W., Barnes N.C., Jeffery P.K. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ Tlymphocytes with FEV1. Am J Respir Crit Care Med 1997, 155:852-857.
7. Saetta M., Stefano A.D., Turato G., Facchini F.M., Corbino L., Mapp C.E., et al. CD8+ T-lymphocites in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:822-826.
8. Fabbri L., Romagnoli M., Corbetta L., Casoni G., Busljetic K., Turato G., et al. Differences in airway inflammmation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. AM J Respir Crit Care Med 2003, 167:418-424.
9. Cosio M.G., Saetta M., Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. New Engl J Med 2009, 360:2445-2454.
10. Traves S.L., Culpitt S.V., Russell R.E., Barnes P.J., Donelly L.E. Increased level of chemokines GROalpha and MCP-1 insputum samples from patients with COPD. Thorax 2002, 57:590-595.
11. Wouters E.F.M., Reynaert N.L., Dentener M.A., Vernooy J.HJ. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009, 6:638-647.
12. Chapman R.W., Minnicozzi M., Celly C.S., Phillips J.E., Kung T.T., Hipkin R.W., et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007, 322:486-493.
13. Ebert L.M., Schaerli P., Moser B. Chemokine-mediated control on T cell traffic in lymphoid and peripheral tissues. Mol Inmunol 2005, 42:799-809.
14. Boschetto P., Quintavalle S., Zeni E., Leprotti S., Potena A., Ballerin L., et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease Thorax 2006, 61:1037-1042.
15. Núñez-Naveira L., Montero-Martinez C., Ramos-Borbón Oxidación, inflamación y modificaciones estructurales. Arch Bronconeumol 2007, 43:18-29.
16. Costa C., Rufino R., Traves S.L., Silva J.R.L., Barnes P.J., Donnelly L.E. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008, 133:26-33.
17. Kelsen S.G., Aksoy M.O., Hershman R., Ji R., Li X., Hurford M., et al. Lymphoid follicle cells in chronic obstructive pulmonary disease overexpress the chemokine receptor CXCR3. Am J Respir Crit Care Med 2009, 179:799-805.
18. Curtis J.L., Freeman C.M., Hogg J.C. The immunopathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007, 4:512-521.
19. Lapperre T.S., Postma S.D., Gosman M.M.E., Snoeck-Stroband J.B., Ten Hacken N.H.T., et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006, 61:115-121.
20. Gamble E., Grootendorst D.C., Hattotuwa K., O'Shaughanessy T., Ram F.S.F., Qiu Y., et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 2007, 30:467-471.
21. Marin A., Monso E., García M., Sauleda J., Noguera A., Pons J., et al. Variability and effects of bronchial colonization in patients with moderate COPD. Eur Respir J 2010, 35:295-302.
22. Di Stefano A., Capelli A., Lusuardi M., Balbo P., Vecchio C., Maestrelli P., et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277-1285.
23. Freeman C.M., Martinez F.J., Han M.K., Ames T.M., Chensue S.W., Todt J.C., et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:1179-1188.
24. Turato G., Zuin R., Miniati M., Baraldo S., Rea F., Beghé B., et al. Airway inflammation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:105-110.
25. Keatings V.M., Collins P.D., Scott D.M., Barnes P.J. Differences in iterleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153:530-534.
26. Vernooy J.H., Kucukaycan M., Jacobs J.A., Chavannes N.H., Buurman W.A., Dentener M.A., et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:1218-1224.
27. Hurst J.R., Wilkinson T.M.A., Perera W.R., Donaldson G.C., Wedzicha J.A. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005, 127:1219-1226.
28. Donaldson G.C., Seemungal T.A.R., Patel I.S., Bhowmik A., Wilkinson T.M.A., Hurst J.R., et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005, 128:1995-2004.
29. Hogg J.C., Chu F.S.F., Tan W.C., Sin D.C., Patel S.A., Pare P.D., et al. Survival after lung volumen reduction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:454-459.
30. Agustí A. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:367-370.
31. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 2004, 59:574-580.
32. Agustí A. EPOC e inflamación sistémica. Una vía de enlace para la comorbilidad. Arch Bronconeumol 2009, 45:14-17.
33. Guerra S., Sherrill D.L., Venker C., Ceccato C.M., Halonen M., Martinez F.D. Chronic bronchitis befote age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009, 64:894-900.
34. Groenewegen K.H., Postma D.S., Hop W.C., Wielders P.L., Schlösser N.J., Wouters E.F. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133:350-357. COSMIC Study Group.
35. Barnes P.J. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2009, 41:631-638.
36. Pinto-Plata V., Toso J., Lee K., Park D., Bilello J., Mullerova H., et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007, 62:595-601.
37. Thorleifsson S.J., Margretardottir O.B., Gudmundsson G., Olafsson I., Benediktsdottir B., Janson C., et al. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med 2009, 103:1548-1553.
38. Higashimoto Y., Iwata T., Okada M., Satoh H., Fukuda K., Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009, 103:1231-1238.
39. De Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., Muros de Fuentes M., Montejo de Garcini A., Aguirre-Jaime A., et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006, 27:902-907.
40. Casanova C., De Torres J.P., Montes de Oca M. Enfermedad pulmonar obstructiva crónica: aspectos sistémicos y factores pronósticos. Arch Bronconeumol 2007, 43:25-34.
41. Vestbo J., Prescott E., Almdal T., Dahl M., Nordestgaard B.G., Andersen T., et al. Body mass, fat-free body mass and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006, 173:79-83.
42. Wagner P.D. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008, 31:492-501.
43. Casanova C., De Torres J.P., Martín M.A. EPOC y malnutrición. Arch Bronconeumol 2009, 45:31-35.
44. Barreiro E., Schols A.M., Polkey M.I., Galdiz J.B., Gosker H.R., Swallow E.B., et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax 2008, 63:100-107.
45. Bolton C.E., Ionescu A.A., Shiels K.M., Pettit R.J., Edwards P.H., Stone M.D., et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:1286-1293.
46. Bolton C.E., Stone M.D., Edwards P.H., Duckers J.M., Evans W.D., Shale D.J. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009, 6:81-87.
47. Jimenez R., De Miguel J., Rejas J., Martín A., Gobartt E., Hernandez V., et al. Health, treatment and health care resources consumption profile among spanish adults with diabetes and chronic obstructive pulmonary disease. Prim Care Diabetes 2009, 3:141-148.
48. Van Eeden S.F., Sin D.D. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008, 75:224-238.
49. Di Marco F., Verga M., Reggente M., María Casanova F., Santus P., Blasi F., et al. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med 2006, 100:1767-1774.
50. Eagan T.M., Ueland T., Wagner P.D., Hardie J.A., Mollnes T.E., Damås J.K., et al. Systemic inflammatory markers in chronic obstructive pulmonary disease -results from the Bergen COPD Cohort Study 2010, 35:540-548.
51. John M., Hoernig S., Doehner W., Okonko D.D., Witt C., Anker S.D. Anemia and inflammation in COPD. Chest 2005, 127:825-829.
52. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
53. Gibbons M.A., Sethi T. Chronic obstructive pulmonary disease and lung cancer: inflammation the missing link. Therapy 2009, 6:805-820.
54. De Torres J.P., Bastarrika G., Wisnivesky J.P., Alcaide A.B., Campo A., Seijo L.M., et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007, 132:1932-1938.
55. Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
56. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., Nordestgaard B.G. C-reactive protein as a predictor of prognosis in COPD. Am J Respir Crit Care Med 2007, 175:250-255.
57. De Torres J.P., Pinto-Plata V., Casanova C., Mullerova H., Córdoba-Lanús E., Muros de Fuentes M., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133:1336-1343.
58. Lomas D.A., Silverman E.K., Edwards L.D., Locantore N.W., Miller B.E., Horstman D.H., Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009, 34:95-102.
59. Sims M.W., Tal-Singer R.M., Kierstein S., Musani A.I., Beers M.F., Panettieri R.A., Haczku A. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008, 9:13.
60. Gooptu B., Lomas D.A. Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med 2008, 205:1529-1534.
61. Ning W., Li C.J., Kaminski N., Feghali-Bostwick C.A., Alber S.M., Di Y.P., et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004, 101:14895-14900.
62. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
63. Gingo M.R., Silveira L.J., Miller Y.E., Friedlander A.L., Cosgrove G.P., Chan E.D., et al. Tumour necrosis factor gene polymorphisms are associated with COPD. Eur Respir J 2008, 31:1005-1012.
64. Smolonska J., Wijmenga C., Postma D.S., Boezen H.M. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med 2009, 180:618-631.
65. Tanaka G., Sandford A.J., Burkett K., Connett J.E., Anthonisen N.R., Paré P.D., et al. Tumour necrosis factor and lymphotoxin a polymorphisms and lung function in smokers. Eur Respir J 2007, 29:34-41.
66. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376.
67. Seifart C., Dempfle A., Plagens A., Seifart U., Clostermann U., Müller B. TNF-a-, TNF-b-, IL- 6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 2005, 65:93-100.
68. Broekhuizen R., Wouters E.F., Creutzberg E.C., Schols A.M. Elevated CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61:17-22.
69. He J.Q., Foreman M.G., Shumansky K., Zhang X., Akhabir L., Sin D.D., et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 2009, 64:698-704.
70. Cordoba-Lanus E., De Torres J.P., Lopez-Aguilar, Rodriguez-Perez M- C., Maca-Meyer N., Montejo-de-Garcini A., et al. Association of IL-6 gene polymorphism and COPD in a Spanish population. Resp Med 2008, 102:1805-1811.
71. Yanbaeva D.G., Dentener M.A., Spruit M.A., Houwing-Duistermaat J.J., Kotz D., Passos V.L., et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet 2009, 10:23.
72. Van Durme Y.M., Verhamme K.M., Aarnoudse A.J., Van Pottelberge G.R., Hofman A., Witteman J.C., et al. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:375-382.
73. Hull J., Thomson A., Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000, 55:1023-1027.
74. Arinir U., Klein W., Rodhe G., Stemmler S., Epplen J., Schulte-Werninghaus G. Polymorphisms in the interleukin-8 gene in patientes with chronic obstructive pulmonary disease. Electrophoresis 2005, 26:2888-2891.
75. Matheson M., Ellis J., Raven J., Walters E., Abramson M. Association of IL-8, CXCR2 and TNF-a polimorphisms and airway disease. J Hum Genet 2006, 51:196-203.
76. Barnes P.J., Adcock I.M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005, 25:552-563.
77. Ito K., Ito M., Elliott W.M., Cosio B., Caramori G., Kon O.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352:1967-1976.